Cases of severely exacerbated CNS inflammation have been described in patients with MS under treatment with alemtuzumab, a pan-lymphocyte--depleting anti-CD52 monoclonal antibody.^[@R1],[@R2]^ On the basis of the peripheral lymphocyte subset network (higher B-cell and suppressed T-cell counts)^[@R2]^ and marked clinical improvement following plasmapheresis and rituximab treatment (anti-CD20 antibody),^[@R1]^ a B-cell--driven intrathecal autoimmune reaction was hypothesized.

Case report. {#s1-1}
============

On January 2017, 4 months after the first course of alemtuzumab, a 27-year-old woman affected by an aggressive form of relapsing remitting MS referred to our MS Centre with a dramatic acute clinical deterioration.

The patient had been diagnosed with MS in 2011, and since the beginning, the disease presented a severe course, with frequent relapses and increased disability in the first year (Expanded Disability Status Scale \[EDSS\] = 3.0). For these reasons, natalizumab was started on June 2012, with no further evidence of clinical and neuroradiologic disease activity until November 2015, when the patient decided to plan a pregnancy that was safely carried out on July 2016. Two weeks after delivery, she had a relapse with an increased disability. Cerebral MRI disclosed new gadolinium-enhancing lesions and the reactivation of previous lesions. CSF analysis was performed ([figure](#F1){ref-type="fig"}), and JC virus (JCV)-DNA PCR was negative. Considering the disease course and the high JCV index (\>2.0), the patient was treated with alemtuzumab (September 2016).

![MRI and immunologic findings\
Brain (A.a--C.a = fluid-attenuated inversion recovery sequences, A.b--C.b = postcontrast T1 sequences) and cervical spinal cord (D.a = T2-weighted sequences, D.b = postcontrast T1 sequences) MRI imaging disclosed several active white matter lesions, many with ring-enhanced morphology. (E, F) IgG isoelectric focusing of paired serum (S) and CSF samples. Compared with the bands detected in August 2016 (E and \* in F), during the episode of CNS inflammation following the first alemtuzumab course (February 2017, F), new serum- (\<) or CSF- (\>) restricted IgG oligoclonal bands were identified. Of interest, a CSF-restricted IgG band detected in August 2016 was found to be mirrored by a serum band in February 2017. (G, H) Analysis of T-helper (CD45^+^CD3^+^CD4^+^) cell subsets in the peripheral blood disclosed an almost complete suppression of T~FR~ (CXCR5^+^PD1^+^CD25^+^CD127dim) lymphocytes in the presence of detectable T~FH~ (CXCR5^+^PD1^+^CD25^−^CD127^+^), T~reg~ (CXCR5^−^CD25^+^CD127dim), and T-helper (CXCR5^−^CD25^−^CD127^+^) cells. (I) Plot shows the proportion of CSF B cells (CD45^+^CD19^+^,12.5%) over the total CD45^+^ leukocyte population (almost all constituted by lymphocytes). (J, K) CSF B cells (J) showed higher values on physical parameters compared with peripheral B cells (K), suggesting an activated status. (L) Compared with peripheral B cells, CSF B cells displayed significant differences in the expression of CD20, CD38, and CD83, suggesting a plasmablast/plasmacells phenotype.](NEURIMMINFL2017013862f1){#F1}

In January 2017, the patient presented with a severe polysymptomatic relapse with dramatic clinical deterioration (EDSS = 7.5). Brain and spinal cord MRIs revealed several contrast-enhancing lesions (most of which were ring-enhancing lesions) disseminated in the brain and cervical spinal cord ([figure](#F1){ref-type="fig"}). CSF examination was repeated and disclosed a significant qualitative change of the oligoclonal IgG band pattern in both serum and CSF compared with that detected in August 2016 ([figure](#F1){ref-type="fig"}). Before starting rescue therapy, T-cell and B-cell subpopulation analyses were performed in peripheral blood (PB) and CSF. In the PB, the total lymphocyte count was 0.8 × 10^9^/L; CD45^+^CD19^+^ cells (B cells) were 0.18 × 10^9^/L (22%); and CD3^+^CD4^+^ (T cells) cells were 0.14 × 10^9^/L (18%). Almost all (98%) circulating B cells were CD20^+^. No trace of T follicular regulatory lymphocytes (T~FR~, CD3^+^CD4^+^CD127^dim^CD25^+^CXCR5^+^PD1^+^) could be found in blood and CSF, in front of detectable T follicular helper lymphocytes (T~FH~, CD3^+^CD4^+^CD127^+^CD25^−^CXCR5^+^PD1^+^) ([figure](#F1){ref-type="fig"}).

In the CSF, B cells represented 12.5% of all lymphocytes, of which 40% were CD20^−^ and displayed high values of physical parameters, suggesting an active state. Moreover, 48% expressed high levels of CD38, and 61% (vs 4% of peripheral B cells) expressed the activation marker CD83, recently demonstrated to play a role during germinal center maturation.^[@R3]^

Despite plasmapheresis (5 sessions), the patient continued to deteriorate, and 6 days of high-dose IV methylprednisolone (1 g/d IV) yielded only a very mild clinical improvement. Two weeks later, the patient had a further worsening, and brain MRI disclosed numerous ring-enhanced lesions. The patient had no signs or symptoms of infectious disease, and detailed immunologic and microbiologic screenings in blood and CSF gave negative results. The search for Epstein-Barr virus DNA in blood and CSF by means of reverse transcription PCR was also negative. The patient had no further autoimmune pathologies. Given the malignant course of the disease, the autologous stem cell transplantation was planned.

Discussion. {#s1-2}
===========

Our case adds new important observations that may shed light on the immunopathologic process occurring in patients with MS who develop severe CNS inflammation following alemtuzumab therapy. Indeed, our findings converge to indicate a primary B-cell--mediated pathology triggered by the therapy. First, the appearance of new IgG bands in serum and CSF implies the activation and maturation of B-cell clones both in the periphery and in the CNS. Second, the presence of T~FH~ (a lymphocyte subpopulation that plays a pivotal role in peripheral follicular reaction)^[@R4]^ along with the absence of T~FR~ (that overlook B-cell maturation in the germinal center)^[@R5]^ suggests an imbalanced T~FH~/T~FR~ ratio and, thus, a dysregulated follicular reaction. Third, the number and the phenotypic profile of CSF B cells point out to an abnormal proliferation of plasmablasts/plasmacells^[@R6]^ within the CNS. Moreover, all these observations were acquired in the time frame in which peripheral B-cell repopulation occurs after alemtuzumab infusion.^[@R7]^

In some patients, the mismatched reconstitution of B and T lymphocytes following alemtuzumab likely opens up to a potentially dangerous time window where autoreactive B-cell clones proliferate in the absence of the appropriate T-cell control. Whether this disorder is an MS rebound or a new CNS inflammatory entity needs to be studied in larger number of subjects. Considering that alemtuzumab is highly effective in the majority of the treated patients, multicentre studies aimed at identifying those who are susceptible to develop severe alemtuzumab-induced CNS inflammation are urgently needed.
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